N/A N=319 Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial
Drug-induced Nausea and Vomiting
Primary: Number of Participants Experiencing Symptoms — 45; 19 Participants — p=0.00
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=12 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia
Familial Dysautonomia
Primary: Composite Daily Score — 6.9; 9.7 units on a scale
N/A N=100 Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery
Nausea and Vomiting Post-foregut Surgery
Primary: Comparison of Postoperative Nausea and Vomiting Scores Between Groups Treated With a ReletexTM Device and Those Without the Device. — 1.81; 2.03 units on a scale
Phase 2 N=30 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Phase 2 N=22 Emend for Multiple-day Emetogenic Chemotherapy
Nausea · Vomiting
Primary: Complete Response (Percentage of Patients) — 84 percentage of participants
Phase 3 N=14 Sancuso® for Gastroparesis: An Open Label Study.
Gastroparesis
Primary: GCSI-DD Total Composite Symptom Scores. — 1.89; 1.57; 1.34 score on a scale — p=<0.01
N/A N=100 Opioid-free Analgesia for the Management of Acute Post-operative Pain Following Caesarean Section
Acute Post-operative Pain Following Caesarean Section
Primary: Post-operative Pain Scores Following Caesarean Section at 4 Hours Post-operative — 2.98; 3.16 score on a scale
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
Phase 2 N=144 Olanzapine for Nausea After Surgery
Postoperative Nausea and Vomiting
Primary: Number of Participants With Nausea and/or Vomiting — 10; 26 Participants — p=0.003
Phase 3 N=91 Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
Chemotherapy-induced Nausea and Vomiting
Primary: Number of Participants With Complete Response — 13; 21; 33; 24 Participants
Phase 2 N=83 Acupressure and Relaxation for Nausea Control
Nausea
Primary: Five-day Nausea Diary — 2.0; 2.1; 2.1; 1.9 Units on scale — p=0.932
N/A N=63 NSS-2 BRIDGE Device in Post-Operative Pain Management
Acute Pain · Surgery · Abdominal Cancer
Primary: Opioid Consumption — 24; 38; 24; 27 oral morphine mg equivalents (OME)
Phase 3 N=42 Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis
Chronic Rhinosinusitis (Diagnosis)
Primary: Pain Visual Analogue Scale (VAS) — 3.3; 2.3 units on a scale — p=<0.05
Phase 3 N=690 Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Malignant Neoplasm
Primary: No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and…
N/A N=5 NSS-Bridge Device for Post-Cesarean Delivery Pain
Acute Pain · Cesarean Delivery
Primary: Opioid Consumption — 31 milligrams of oxycodone